Compare AXTI & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXTI | BBNX |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 1998 | 2025 |
| Metric | AXTI | BBNX |
|---|---|---|
| Price | $17.92 | $16.79 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $11.05 | ★ $29.75 |
| AVG Volume (30 Days) | ★ 7.4M | 1.4M |
| Earning Date | 02-19-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $90,390,000.00 | $88,570,000.00 |
| Revenue This Year | N/A | $53.22 |
| Revenue Next Year | $33.52 | $35.58 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 67.01 |
| 52 Week Low | $1.13 | $8.89 |
| 52 Week High | $26.66 | $32.71 |
| Indicator | AXTI | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 48.35 | 27.17 |
| Support Level | $20.00 | $16.02 |
| Resistance Level | $26.66 | $19.03 |
| Average True Range (ATR) | 3.20 | 1.92 |
| MACD | -0.52 | -1.06 |
| Stochastic Oscillator | 27.57 | 4.38 |
AXT Inc is a developer and producer of compound and single element semiconductor substrates, also known as wafers. The dominant substrates used in producing semiconductor chips and other electronic circuits are made from silicon. It is engaged in the design, development, manufacture, and distribution of high-performance compound semiconductor substrates and the sale of materials. The company provides alternative or specialty materials in the form of substrates or wafers, including compound and single-element substrates. Its compound substrates combine indium with phosphorous or gallium with arsenic. Geographically firm has its business presence across the region of Europe, Japan, Taiwan, China, North America, and the Asia Pacific from which China derives its maximum revenue to the company.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.